Objectives: To validate and accredit a set of three multiplex endpoint PCR assays, targeting the most important carbapenemase and minor extended-spectrum b-lactamase (ESBL) resistance genes, according to the international ISO 15189 particular requirements for the quality and competence of medical laboratories.
Introduction
The worldwide spread of genes conferring resistance to broad spectrum b-lactams including carbapenems in Gram-negative bacteria is a source of global concern.
1 -3 Class A extendedspectrum b-lactamase (ESBL)-encoding genes such as bla TEM , bla SHV and especially bla CTX-M have largely disseminated worldwide among Enterobacteriaceae. Other bla genes encoding minor ESBLs (bla BEL, bla VEB, bla GES and bla PER ) are more rarely reported, although they have also been observed worldwide especially among Gram-negative non-fermenters. 4 Even more worrying is the recent emergence and spread of genes encoding carbapenemases. 3 Although class D carbapenem-hydrolysing b-lactamases of group OXA-23, OXA-24, OXA-58 or OXA-143 type are almost exclusively reported in Acinetobacter baumannii, 5 OXA-48 (and related types) seems to be exclusively and widely expressed in Enterobacteriaceae. 6 Besides OXA-48, the spread of carbapenemases of class A (KPC and some GES variants such as GES-2 and GES-5) and of class B (VIM, IMP and NDM) have been reported, albeit at differing frequencies, in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. 1, 7, 8 Rapid and reliable detection methods are important for the early implementation of infection control measures and for preventing the subsequent dissemination of ESBLs and of carbapenemases. Although a promising, rapid and easy detection method based on the antibiotic hydrolytic properties of the expressed b-lactamases has been recently published, 9,10 confirmation and identification of the precise types of b-lactamase genes involved still need the use of molecular PCR-based methods.
There is a plethora of PCR methods described in the literature that are often validated only internally. 11 -15 Nevertheless, quality standards requirements for medical laboratories are now evolving as a general rule, and compliance with the international ISO 15189 requirements for the quality and competence of medical laboratories is becoming mandatory. 16 The accreditation process according to ISO 15189 represents a highly challenging task for medical laboratories. One particular difficulty is related to the fact that these requirements have to be fulfilled, but there are no universal ways or hints about how to reach them.
We present here the validation scheme for three multiplex endpoint PCR assays targeting some of the most epidemiologically relevant carbapenemases (PCR CARBA targeting bla VIM, bla IMP, bla NDM, bla KPC and bla OXA-48 and PCR OXACARBA targeting bla OXA-23, bla OXA-24 and bla OXA-58 ) and the minor ESBLs (PCR MINESBL targeting bla BEL, bla GES, bla PER and bla VEB ). The latter two tests were particularly important for our activity of reference centre as no commercial assay is currently available for these targets. These PCR assays were validated and accredited according to the international ISO 15189 standards after an external audit performed by the Belgian accreditation body BELAC. This validation scheme could be useful for implementing accredited home-made PCRs in the routine laboratory. Design of primers (Table 2) For each gene family, all alleles referenced on the Lahey Clinic web site (http://www.lahey.org/Studies/) were uploaded from GenBank databases and aligned using the ClustalX software version 2.0. Primers were designed within the common coding region of the published alleles. An additional primer pair that targets the chromosomal AmpC of A. baumannii (bla ADC ) was used as an internal PCR/extraction control. All the primers apart from the forward primer targeting bla VEB 17 were designed in our laboratory.
Materials and methods

Bacterial isolates (
DNA extraction and multiplex PCR assays
A single colony was suspended in 200 mL of distilled water, and 10 mL of a McFarland 3 turbidity standard of A. baumannii ATCC 19606 was added to the suspension before extraction as an internal extraction control (958C for 10 min in a dry bath). The 25 mL amplification mixture contained 2 mL of DNA extract, 12.5 mL of 2 × master mix multiplex PCR Kit (Qiagen Benelux, Antwerp, Belgium) and 200 mM of each primer (except for IMP, for which the concentration of the primers was raised to 600 mM). PCR was performed on a ABI 2720 thermocycler (Life Technologies Europe BV, Gent, Belgium) under the following conditions: 15 min at 958C and 30 cycles of 30 s denaturation at 948C; 90 s annealing at 578C and 90 s elongation at 728C; and a final elongation step at 728C for 10 min.
Each PCR run had to include three PCR controls: a positive resistance gene control including each of the targeted genes, a DNA extraction positive control including only the internal extraction control suspended in water, and a negative control (only water, no DNA). The amplicons were visualized by capillary electrophoresis on a QIAxcel instrument (Qiagen Benelux) using the QIAxcel high-resolution kit, QX DNA size marker 100-2500 bp and QX alignment markers 15/5000 bp according to the manufacturer's recommendations. The whole process, including extraction and electrophoresis takes ,4 h. A negative result could only be technically validated when the band corresponding to the internal extraction control was present. In case of a positive result for any of the targeted genes, the presence of the internal control does not need to be taken into account.
Validation process
The validation process was based on the procedure proposed by Rabenau et al. 18 for home-made qualitative nucleic acid testing. This process includes the control of the specificity, sensitivity, reproducibility and accuracy of each PCR multiplex assay. For sensitivity, at least 10 different isolates positive for the gene to be detected were tested once. In cases where the minimum number of isolates harbouring the targeted genes was not available in the library, the available isolates were extracted twice or more so as to reach 10 different sample preparations. For specificity, at least 20 isolates known to be negative for the targeted genes, but possibly expressing other resistance genes representative of the current b-lactamase epidemiology, were tested once. For reproducibility, one isolate positive for each resistance gene was tested three times intra-run and three times inter-run. Finally, accuracy was certified by testing a panel prepared and sent by an external laboratory [external quality control (EQC) process] comprising three positive isolates for each target to be tested and three negative ones. This panel equally comprised referenced isolates from the TEMPOtest-QC collection.
Results and discussion
The three multiplex PCR assays were validated with a panel of 137 characterized and referenced Gram-negative clinical isolates (Table 1) according to the validation protocol presented in the 'Materials and methods' section. This collection includes 30 metallo-b-lactamase-expressing isolates (10 VIM-, 10 IMPand 10 NDM-expressing isolates), 10 OXA-48-expressing isolates, 10 KPC-expressing isolates, 31 OXA-23, OXA-24 or OXA-58-expressing isolates, 41 minor ESBL-expressing isolates (BEL, VEB, GES and PER), 27 TEM-expressing isolates, 26 SHVexpressing isolates and 14 CTX-M-expressing isolates. In addition, 33 isolates expressing additional b-lactamases not targeted by the PCR assays were used for specificity testing.
For each multiplex PCR assay, the presence of an extraction control ruled out false-negative results due to PCR inhibition or extraction faults. In the positive resistance gene control, the presence of each band at the expected size confirms the ability of the PCR to detect up to five resistance genes in a single PCR (Figure 1) . The positive extraction PCR control has to be performed in a separate well as the corresponding 1059 bp amplicon tends to disappear in the presence of another resistance gene. It highlights that the extraction/inhibition control does not interfere with the detection of the targeted resistance genes generating smaller amplicons. Sensitivity, specificity and reproducibility (including the extraction step) for each of the targeted genes were 100% (data not shown). The resistance genes of the isolates included in the three EQC panels were correctly identified by each PCR assay (accuracy 100%; Figure 1 ). Regarding specificity, non-specific amplifications generating fragments of unexpected sizes were observed in about 2% of the cases, and have to be interpreted as negative results (Figure 1b, lane 1) . These non-specific results were often related to an Enterobacter asburiae isolate (data not shown). No explanation could be found to explain this phenomenon, although it was less frequently observed when the primers were HPLC purified and was not observed when the PCR was performed in simplex for each individual target. The validation files were controlled by BELAC during an external audit held in UCL Mont-Godinne on 19 March 2012, and the three PCR protocols were accepted for accreditation according to ISO 15189 in July 2012 (BELAC Certificate 431-MED).
It is important to point out that, according to ISO 15189, an efficient separation between the different work areas must be provided in order to efficiently avoid cross-contamination. All the processes described here only represent the analytical part of the accreditation process. Pre-analytical and post-analytical stages must also follow ISO 15189 standards, but these are more difficult to export from one laboratory to another. Many excellent home-made PCRs (endpoint or real-time) have already been published in the literature (e.g. Dallenne et al., 11 Huang et al., 12 Naas et al., 13 Poirel et al., 14 Swayne et al. 15 and Naas et al., 19 although many other publications exist). Regarding other multiplex PCRs for carbapenemases, each method presents its own characteristics. For example, Huang et al. 12 proposed a real-time TaqMan multiplex targeting different class D carbapenemases from A. baumannii, while Swayne et al. 15 published a TaqMan PCR targeting five class A and D carbapenemases encountered in Enterobacteriaceae. The three multiplex PCR assays presented by Poirel et al.
14 are endpoint PCRs targeting the largest panel of carbapenemase genes (11 targets). The implementation of PCR in a laboratory will depend on its particular needs, local epidemiology, technical resources and quality requirements. Most methods are indeed efficient and have already been peer-reviewed, but they would most probably not be accepted as such by external auditors as conforming to ISO 15189. Major non-conformities with ISO 15189 standards are the lack of an internal control able to rule out false-negative results and the absence of accuracy testing by participating in at least one annual EQC.
Testing accuracy is optimally achieved by participation in external quality assurance schemes organized by independent bodies such as Quality Control for Molecular Diagnostics or the United Kingdom National External Quality Assessment Service. Unfortunately, these bodies do not yet organize EQC evaluations for the detection of resistance genes. In such situations, ISO 15189 accepts that laboratories organize a so-called ring test (a blind exchange of an EQC proficiency panel) to evaluate the accuracy of their own methods. This is what was performed with the strains obtained from the TEMPOtest-QC consortium.
In summary, we report here the successful accreditation process of three home-made multiplex PCR assays according to the ISO 15189 standards. We believe that this validation scheme should constitute a valuable tool for laboratories in order to accredit their own protocols. Moreover, as these three multiplex PCR assays are already accredited, they could easily be implemented in other diagnostic laboratories through a lighter verification procedure.
